Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis

  title={Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis},
  author={Xu Zhao and Xiaofang Zhang and Yang Zhao and Xin Lin and Ning-yin Li and Ganesh Paudel and Qiongyin Wang and Xiao-Wei Zhang and Xiu-li Li and Jing Yu},
  journal={Gynecological Endocrinology},
  pages={685 - 689}
Abstract Postmenopausal hypertensive is associated with estrogen deficiency. This meta-analysis was performed to assess the efficacy and safety of drospirenone combined with 17-β-estradiol (DRSP/E2) in postmenopausal hypertensive women. A systemic literature search of PubMed, Embase, Cochrane Library, Web of Science (up to Oct. 2015) was performed. Studies were screened independently by two researchers according to the inclusion and exclusion criteria which included only the randomized… 

Menopausal hyperinsulinism and hypertension – new approach

E2/DRSP represents suitable therapy for hyperinsulinemic, grade I hypertensive menopausal women with typical symptoms and normal weight.

The use of menopausal hormone therapy in women at high cardiovascular risk

The adoption of clinical decisions on the use of MHT in conditions of high CVR and the presence of individual clinically significant risk factors should be carried out by a multidisciplinary team, which will exclude both unmotivated prohibitions and appointments in the absence of contraindications.

Hormones endogènes et exogènes

Variations in Blood Pressure and Pulse Rate in Phases of Menstrual Cycle in women with Primary Dysmenorrhea

It has been observed that sympathetic nervous activities predominate the luteal phase whereas parasympathetic activities mark the follicular phase, which point towards sympathetic over activity in females with dysmenorrhea.

Hormonersatztherapie und Prävention gemäß S3-Leitlinie

Eine Hormonersatztherapie kann effektiv klimakterische Beschwerden lindern. Darüber hinaus hat sie Wirkungen, die sich positiv auf die Gesundheit auswirken, aber auch die Anwendung limitieren können.

Hormonersatztherapie und Prävention gemäß S3-Leitlinie

The effects are low and contradictory with respect to hormone-dependent tumors so that hormone replacement therapy is not suitable for oncological prophylaxis, and can effectively relieve climacteric complaints.

Uterine haemodynamic, vascularization and blood pressure changes along the oestrous cycle in bitches.

Hemodynamic changes in the uterine artery, uterine diameter, systemic blood pressure and heart rate occur during the canine oestrous cycle, while uterine blood flow diminishes during oestrus and anoestrus.

Usporedba transdermalne i oralne primjene hormonskog nadomjesnog liječenja kod žena u postmenopauzi

Ovaj rad donosi pregled literature o slicnostima i razlikama oralne i transdermalne primjene hormonskog nadomjesnog lijecenja, poglavito estrogena,



Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril.

Antihypertensive Effects of Drospirenone With 17&bgr;-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension

Combination therapy with DRSP/E2 significantly lowered both clinic and 24-hour systolic BP in postmenopausal women with stage 1 systolics hypertension, which may lead to benefit for cardiovascular risk reduction in this population of women.

Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide

DRSP/E2 substantially lowers systolic and diastolic blood pressure when added to existing antihypertensive therapy with HCTZ in hypertensive postmenopausal women and has a potassium-sparing effect that counteracts HCTz-induced potassium loss.

Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens

It is demonstrated that the combinations of 1, 2, and 3’mg drospirenone with 1 mg estradiol are safe and effective for the treatment of climacteric symptoms.

Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study

  • A. PaolettiA. Cagnacci G. Melis
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2015
Differences between the two progestins are mainly limited to body composition (BC), where the addition of DRSP decreases ECW and body W (BW).

One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women

The low-dose, 0.25 mg DRSP/0.5 mg E2 dose combination met the criteria for endometrial safety and demonstrated a favorable risk/benefit profile in this 1-year, double-blind, randomized study of postmenopausal women.

Effects of a New Hormone Therapy, Drospirenone and 17-&bgr;-Estradiol, in Postmenopausal Women With Hypertension

Data show that DRSP combined with E2 significantly reduces BP in postmenopausal women with hypertension and did not induce significant increases in serum potassium, which may lead to a new benefit for this novel hormone therapy in postwomen's hypertension.

Low-dose estrogen and drospirenone combination: effects on metabolism and endothelial function in postmenopausal women with metabolic syndrome.

Drospirenone improves cardiovascular risk factors and does not impair endothelial function in menopausal women with metabolic syndrome.

Effects of estradiol–drospirenone on menopausal symptoms, lipids and bone turnover in Chinese women

  • M. LiA. Wang X. Li
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2015
Estradiol–drospirenone effectively alleviates menopausal symptoms and also has beneficial effects on blood lipids and bone metabolism.